Another biotech games the system, and everyone gets to pay for the fallout
Endpoints assesses the big biopharma R&D stories of the week, with a little added commentary on what they mean for the industry.
The FDA got played – again
As I write, our story on Marathon and its old, cheap steroid — deflazacort — that it steered to an FDA approval yesterday is gaining some serious traction on social media outlets like Reddit. That’s where the online mob formed for Martin Shkreli, after word spread that he and Turing had hiked the price of Daraprim for HIV users by 5000%-plus. And it’s where you can feel the visceral public anger that’s been building over drug prices.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.